Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF).

The association between bridging and adverse events persisted in multivariate-adjusted analysis (Table 4 ): The use of bridging anticoagulation during interruption was significantly associated with an increase in bleeding events (adjusted OR, 3.84 for major bleeding or bleeding hospitalization; 95% confidence interval, 2.07–7.14; P <0.0001) and showed a trend toward increased cardiovascular events (adjusted OR, 1.62; 95% confidence interval, 0.95–2.78; P =0.07).

also in 53,322 other papers